Riskpilot← Back to searchSign inGet full accessSträngnäsvaccin AB
ABActiveOrg 5590044706Brogatan 21General medical practice activities · NACE 8621Est. 20151-4 employees
Revenue 2024
SEK 4,3M
+25% vs 2023
EBITDA margin
3.6%
+291% vs 2023
Equity ratio
90.1%
Financial strength
Net profit 2024
SEK 106K
+149% vs 2023
| Revenue | SEK 4,3M | +25% |
| EBITDA | SEK 155K | +291% |
| Net profit | SEK 106K | +149% |
| Total assets | SEK 1,1M | -7% |
| Equity | SEK 1M | -9% |
| Employees | — | — |
Legal name
Strängnäsvaccin AB
Org number
5590044706
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
18 februari 2015
Share capital
SEK 50 000
Employees
1-4
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Aktiebolaget ska bedriva vacciations- och hälsovårdsverksamhet.
Address
Brogatan 21
Phone
+46730920053
Email
marianne.strangnasvaccin@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 4 180 | 3 792 | 3 524 | 3 456 | 4 306 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 1 253 | 232 | −231 | −81 | 155 |
| Depreciation & amort. | −233 | −140 | −153 | −153 | −30 |
| EBIT | 1 020 | 92 | −384 | −234 | 125 |
| Net financials | — | — | 1 | 16 | 14 |
| Profit before tax | 970 | 599 | −383 | −218 | 138 |
| Tax | −221 | −211 | −144 | −0 | −32 |
| Net profit | 749 | 388 | −527 | −218 | 106 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 736 | 2 401 | 1 678 | 1 227 | 1 142 |
| Equity | 2 150 | 2 246 | 1 531 | 1 127 | 1 029 |
| Long-term debt | 0 | 1 | 6 | 4 | 10 |
| Short-term debt | 80 | 154 | 141 | 96 | 103 |
| Total debt | 80 | 155 | 147 | 100 | 113 |
EBITDA margin
3.6%
This company
15.8%
Market median
-77% vs market
20202024
Equity ratio
90.1%
This company
38.2%
Market median
+136% vs market
20202024
Return on equity
10.3%
This company
18.4%
Market median
+44% vs market
20202024
Net profit margin
2.5%
This company
8.1%
Market median
-69% vs market
20202024
Asset turnover
3.77×
This company
1.12×
Market median
+237% vs market
20202024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
GM Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Strängnäsvaccin AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gullie Marianne Vilander | Chief Executive Officer | 0 companies |
| Lars Jesper Sterne | Chairman | 0 companies |
| Anna-Clara Maria Sterne | Deputy Board Member | 0 companies |